Journal ArticleDOI
Global Cancer Incidence and Mortality Rates and Trends—An Update
Reads0
Chats0
TLDR
Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates.Abstract:
There are limited published data on recent cancer incidence and mortality trends worldwide. We used the International Agency for Research on Cancer's CANCERMondial clearinghouse to present age-standardized cancer incidence and death rates for 2003-2007. We also present trends in incidence through 2007 and mortality through 2012 for select countries from five continents. High-income countries (HIC) continue to have the highest incidence rates for all sites, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates. Mortality rates from these cancers are declining in many HICs while they are increasing in LMICs. LMICs have the highest rates of stomach, liver, esophageal, and cervical cancer. Although rates remain high in HICs, they are plateauing or decreasing for the most common cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only). In contrast, rates in several LMICs are increasing for these cancers due to increases in smoking, excess body weight, and physical inactivity. LMICs also have a disproportionate burden of infection-related cancers. Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.read more
Citations
More filters
Journal ArticleDOI
LncRNA BRE-AS1 interacts with miR-145-5p to regulate cancer cell proliferation and apoptosis in prostate carcinoma and has early diagnostic values.
TL;DR: It is found that plasma BRE-AS1 and miR-145-5p were both down-regulated in PC patients than in healthy controls, which effectively distinguished early-stage PC patients from healthy controls.
Journal ArticleDOI
Blocking inhibition to YAP by ActinomycinD enhances anti-tumor efficacy of Corosolic acid in treating liver cancer.
Yanfeng Xu,Yinghui Zhao,Yanli Xu,Yu Guan,Xiao Zhang,Yan Chen,Qi Wu,Guoqing Zhu,Yuxin Chen,Fenyong Sun,Jiayi Wang,Yongchun Yu +11 more
TL;DR: It is found reduction of Yes-associated protein (YAP) might be a critical event that suppresses efficacy of CA and combined treatment of AD and CA might solve this problem.
Journal ArticleDOI
Supramolecular ultra-short carboxybenzyl-protected dehydropeptide-based hydrogels for drug delivery.
Sérgio Rafael Silva Veloso,Peter J. Jervis,Peter J. Jervis,Joana F. G. Silva,Loic Hilliou,C.G. Moura,David M. Pereira,Paulo J. G. Coutinho,José A. Martins,Elisabete M. S. Castanheira,Paula M. T. Ferreira +10 more
TL;DR: In this paper, a focused library of Cbz-protected peptide-based hydrogels was synthesized and evaluated as minimalist hydrogelators, which were comprehensively evaluated regarding molecular aggregation and self-assembly, gelation, biocompatibility and as drug carriers for delivery of the natural compound curcumin and the clinically important antitumor drug doxorubicin.
Book ChapterDOI
Runx Genes in Breast Cancer and the Mammary Lineage.
Nicholas Rooney,Alessandra I. Riggio,Daniel Mendoza-Villanueva,Paul Shore,Ewan R. Cameron,Karen Blyth +5 more
TL;DR: Evidence to date shows that the RUNX genes can have dualistic outputs with respect to promoting or constraining breast cancer phenotypes, and that this may be aligned to individual subtypes of the clinical disease.
Journal ArticleDOI
Inhibition of tumor growth by mouse ROR1 specific antibody in a syngeneic mouse tumor model.
Hadi Hassannia,Mohammad Mehdi Amiri,Farhad Jadidi-Niaragh,Reza Hosseini-Ghatar,Jalal Khoshnoodi,Ramezan-Ali Sharifian,Forough Golsaz-Shirazi,Mahmood Jeddi-Tehrani,Fazel Shokri,Fazel Shokri +9 more
TL;DR: The results demonstrated for the first time tumor inhibitory effect of mouse ROR1 specific antibody in a syngeneic mouse tumor model, which is a promising tool for preclinical assessment of Ror1 therapeutics and investigation of the underling molecular mechanisms.
References
More filters
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Journal ArticleDOI
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Denise R. Aberle,Amanda M. Adams,Christine D. Berg,William C. Black,Jonathan D. Clapp,Richard M. Fagerstrom,Ilana F. Gareen,Constantine Gatsonis,Pamela M. Marcus,JoRean D. Sicks +9 more
TL;DR: Screening with the use of low-dose CT reduces mortality from lung cancer, as compared with the radiography group, and the rate of death from any cause was reduced.
Journal ArticleDOI
The global health burden of infection-associated cancers in the year 2002.
TL;DR: The fraction of the different types of cancer, and of all cancers worldwide and in different regions, has been estimated using several methods; primarily by reviewing the evidence for the strength of the association (relative risk) and the prevalence of infection in different world areas.
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]
J Ferlay,I Soerjomataram,M Ervik,R Dikshit,S Eser,Colin Mathers,M Rebelo,D.M. Parkin,David Forman,Freddie Bray,S Elser,M Ervick,Donald Maxwell Parkin +12 more
Journal ArticleDOI
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States
TL;DR: The authors update the incidence trends through 1994 and further consider the trends by age group.